Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents

Pharmacology and Therapeutics

Volumn 79, Issue 1, 1998, Pages 55-87

  Foley, Michael ^a   Tilley, Leann ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Chloroquine; Drug resistance; Malaria; Plasmodium; Quinoline antimalarials

Indexed keywords

AMODIAQUINE; CHLOROQUINE; CINCHONINE; ETHOXYQUIN; HALOFANTRINE; MEFLOQUINE; MEPACRINE; PIPERAQUINE; PRIMAQUINE; PYRONARIDINE; QUININE SULFATE; TAFENOQUINE;

ANTIMALARIAL ACTIVITY; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; MALARIA; PARASITE DEVELOPMENT; PARASITE VIRULENCE; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MALARIA; PLASMODIUM; QUINOLINES;

EID: 0031847073     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00012-6     Document Type: Review

References (406)

1. Adams P.A., Berman P.A., Egan T.J., Marsh P.J., Silver J. The iron environment in heme and heme-antimalarial complexes of pharmacological interest. J. Inorg. Biochem. 63:1996;69-77.
2. 3H-chloroquine. Am. J. Pathol. 67:1972;277-284.
3. Allison J.L., O'Brien R.L., Hahn F.E. DNA. reaction with chloroquine Science. 149:1965;1111-1113.
4. Areekul S., Boonme Y. Superoxide dismutase and catalase activities in red cells of patients with Plasmodium falciparum. J. Med. Assoc. Thai. 70:1987;127-131.
5. + exchanger Annu. Rev. Physiol. 47:1985;545-560.
6. Asawamahasakda W., Ittarat I., Chang C.C., McElroy P., Meshnick S.R. Effects of antimalarials and protease inhibitors on plasmodial hemozoin production. Mol. Biochem. Parasitol. 67:1994;183-191.
7. Asindi A.A., Ekanem E.E., Ibia E.O., Nwangwa M.A. Upsurge of malaria-related convulsions in a paediatric emergency room in Nigeria. Consequence of emergence of chloroquine-resistant Plasmodium falciparum. Trop. Geogr. Med. 45:1993;110-113.
8. Atamna H., Ginsburg H. Origin of reactive oxygen species in erythrocytes infected with Plasmodium falciparum. Mol. Biochem. Parasitol. 61:1993;231-241.
9. Atamna H., Ginsburg H. Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. J. Biol. Chem. 270:1995;24876-24883.
10. Atamna H., Pescarmona G., Ginsburg H. Hexose-monophosphate shunt activity in intact Plasmodium falciparum-infected erythrocytes and in free parasites. Mol. Biochem. Parasitol. 67:1994;79-89.
11. Atamna H., Krugliak M., Shalmiev G., Deharo E., Pescarmona G., Ginsburg H. Mode of antimalarial effect of methylene blue and some of its analogs on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem. Pharmacol. 51:1996;693-700.
12. Bangchang K.N., Karbwang J., Back D.J. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. Biochem. Pharmacol. 43:1992;1957-1961.
13. Barasch J., Kiss B., Prince A., Saiman L., Gruenert D., al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature. 352:1991;70-73.
14. Barennes H., Pussard E., Mahaman Sani A., Clavier F., Kahiatani F., Granic G., Henzel D., Ravinet L., Verdier F. Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. Br. J. Clin. Pharmacol. 41:1996;389-395.
15. Barlin G.B., Jiravinyu C. Potential antimalarials. XIII. Mono-Mannich bases of. 4-[7-chloro(and 7-trifluoromethyl quinolin-4ylamino]- and 4-[7-bromo-1,5-napthyridin-4-ylamino]-3-methylphenol. Aust. J. Chem. 41):1991;151-156.
16. Barlin G.B., Yan H. Potential antimalarials. VIII. Mono- and di-Mannich bases of. 2-(7′trifluoromethylquinolin-4′-ylaminophenol via 2-nitrophenols. Aust. J. Chem. 42):1989;2191-2199.
17. Barlin G.B., Jiravinyu C., Butcher G.A., Kotecka B., Rieckmann K. The in vitro and in vivo antimalarial activity of some Mannich bases derived from 4-(7′-trifluoromethyl-1′,5′-naphthyridin-4′-ylamino) phenol, 2-(7′-trifluoromethyl-quinolin-4′-ylamino)phenol, and 4′-chloro-5-(7′′-trifluoromethylquinolin-4′′- ylamino)biphenyl-2-ols. Ann. Trop. Med. Parasitol. 86:1992;323-331. a.
18. Barlin G.B., Nguyen T.M.T., Kotecka B., Rieckmann K.H. Potential antimalarials. XV. Di-Mannich bases of. 2-[7-chloroquinolin-4′ylamino]phenol(and 2-[7′-bromo(and trifluoromethyl)-1′,5′-napthyridin-4′-ylamino]phenol Aust. J. Chem. 45):1992;1651-1662. b.
19. Barnes D.A., Foote S.J., Galatis D., Kemp D.J., Cowman A.F. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J. 11:1992;3067-3075.
20. Barrett P.J., Emmins P.D., Clarke P.D., Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis. postal and telephone survey of travellers Br. Med. J. 313:1996;525-528.
21. Basco L.K., Le Bras J. Reversal of chloroquine resistance with cyproheptadine in "wild" strains of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 85:1991;204-205.
22. Basco L.K., Gillotin C., Gimenez F., Farinotti R., Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br. J. Clin. Pharmacol. 33:1992;517-520.
23. Basco L.K., Andersen S.L., Milhous W.K., Le Bras J., Vennerstrom J.L. In vitro activity of bisquinoline WR268,668 against African clones and isolates of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 50:1994;200-205.
24. Basco L.K., Le Bras J., Rhoades Z., Wilson C.M. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol. Biochem. Parasitol. 74:1995;157-166.
25. Basilico N., Monti D., Olliaro P., Taramelli D. Non-iron porphyrins inhibit β-haematin (malaria pigment) polymerisation. FEBS Lett. 409:1997;297-299.
26. Beadle C., Hoffman S.L. History of malaria in the United States Naval Forces at war. World War I through the Vietnam conflict Clin. Infect. Dis. 16:1993;320-329.
27. Beaudoin R.L., Aikawa M. Primaquine-induced changes in morphology of exoerythrocytic stages of malaria. Science. 160:1968;1233-1234.
28. Bécuwe P., Slomianny C., Camus D., Dive D. Presence of an endogenous superoxide dismutase activity in three rodent malaria species. Parasitol. Res. 79:1993;349-352.
29. Bendrat K., Berger B.J., Cerami A. Haem polymerisation in malaria. Nature. 378:1995;138-139.
30. Berger B.J., Martiney J., Slater A.F.G., Fairlamb A.H., Cerami A. Chloroquine resistance is not associated with drug metabolism in Plasmodium falciparum. J. Parasitol. 81:1995;1004-1008.
31. Berman A., Shearing L.N., Ng K.F., Jinsart W., Foley M., Tilley L. Photoaffinity labelling of Plasmodium falciparum proteins involved in phospholipid transport. Mol. Biochem. Parasitol. 67:1994;235-243.
32. Bernstein H.N. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am. J. Med. 75:1983;25-34.
33. Bernstein H.N. Ocular safety of hydroxychloroquine. Ann. Ophthalmol. 23:1991;292-296.
34. Bitonti A.J., Sjoerdsma A., McCann P.P., Kyle D.E., Oduola A.M., Rossan R.N., Milhous W.K., Davidson D.E. Reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum by desipramine. Science. 242:1988;1301-1303.
35. Bjorkman A., Phillips-Howard P.A. Drug-resistant malaria. mechanisms of development and inferences for malaria control Trans. R. Soc. Trop. Med. Hyg. 84:1990;323-324.
36. Blauer G. Interaction of ferriprotoporphyrin IX with the antimalarials amodiaquine and halofantrine. Biochem. Int. 17:1988;729-734.
37. Blauer G., Akkawi M. B-hematin. Biochem. Mol. Biol. Int. 35:1995;231-235.
38. Blauer G., Akkawi M. Investigations of B- and β-hematin. J. Inorg. Biochem. 66:1997;145-152.
39. Bloland P.B., Lackritz E.M., Kazembe P.N., Were J.B., Steketee R., Campbell C.C. Beyond chloroquine. implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa J. Infect. Dis. 167:1993;932-937.
40. Bohle D.S., Dinnebier R.E., Madsen S.K., Stephens P.W. Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction. J. Biol. Chem. 272:1997;713-716.
41. Borst P., Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49:1995;427-460.
42. + antiport of Plasmodium falciparum membrane. J. Cell. Physiol. 154:1993;527-534.
43. Boudreau E.F., Webster H.K., Pavanand K., Thosingha L. Type II mefloquine resistance in Thailand. Lancet ii: 1335:1982.
44. Boulard Y., Landau I., Miltgen F., Ellis D.S., Peters W. The chemotherapy of rodent malaria, XXXIV. Causal prophylaxis Part III. ultrastructural changes induced in exo-erythrocytic schizonts of Plasmodium yoelii yoelii by primaquine Ann. Trop. Med. Parasitol. 77:1983;555-568.
45. Boulter M.K., Bray P.G., Howells R.E., Ward S.A. The potential of desipramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Trans. R. Soc. Trop. Med. Hyg. 87:1993;303.
46. Bouma M.J., Sondorp H.E., van der Kaay H.J. Climate change and periodic epidemic malaria. Lancet. 343:1994;1440.
47. Brasseur P., Kouamouo J., Moyou R.S., Druilhe P. Emergence of mefloquine-resistant malaria in Africa without drug pressure. Lancet. 336:1990;59.
48. Bray P.G., Howells R.E., Ritchie G.Y., Ward S.A. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem. Pharmacol. 44:1992;1317-1324.
49. Bray P.G., Boulter M.K., Ritchie G.Y., Howells R.E., Ward S.A. Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 63:1994;87-94.
50. Bray P.G., Hawley S.R., Mungthin M., Ward S.A. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol. Pharmacol. 50:1996;1559-1566. a.
51. Bray P.G., Hawley S.R., Ward S.A. 4-Aminoquinoline resistance of Plasmodium falciparum. insights from the study of amodiaquine uptake Mol. Pharmacol. 50:1996;1551-1558. b.
52. Bryson H.M., Goa K.L. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs. 43:1992;236-258.
53. Bunnag D., Karbwang J., Na-Bangchang K., Thanavibul A., Chittamas S., Harinasuta T. Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J. Trop. Med. Public Health. 27:1996;15-18.
54. Carroll F.I., Blackwell J.T. Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry. J. Med. Chem. 17:1974;210-219.
55. Carson P.E., Hohl R., Nora M.V., Parkhurst G.W., Ahmad T., Scanlan S., Frischer H. Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. Bull. WHO. 59:1981;427-437.
56. Chang C., Lin-Hua T., Jantanavivat C. Studies on a new antimalarial compound. pyronaridine Trans. R. Soc. Trop. Med. Hyg. 86:1992;7-10.
57. Chavalitshewinkoon P., de Vries E., Stam J.G., Franssen F.F., van der Vliet P.C., Overdulve J.P. Purification and characterization of DNA polymerases from Plasmodium falciparum. Mol. Biochem. Parasitol. 61:1993;243-254.
58. Chen L. Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine. Chin. Med. J. 104:1991;161-163.
59. Chen L., Qu F.-Y., Zhou Y.C. Field observations on the antimalarial piperaquine. Chin. Med. J. 95:1982;282-286.
60. Chevli R., Fitch C.D. The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob. Agents Chemother. 21:1982;581-586.
61. Chou A.C., Fitch C.D. Mechanism of hemolysis induced by ferriprotoporphyrin IX. J. Clin. Invest. 68:1981;672-677.
62. Chou A.C., Fitch C.D. Heme polymerase. modulation by chloroquine treatment of a rodent malaria Life Sci. 51:1992;2073-2078.
63. Chou A.C., Fitch C.D. Control of heme polymerase by chloroquine and other quinoline derivatives. Biochem. Biophys. Res. Commun. 195:1993;422-427.
64. Chou A.C., Chevli R., Fitch C.D. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry. 19:1980;1543-1549.
65. Churchill F.C., Patchen L.C., Campbell C.C., Schwartz I.K., Nguyen-Dinh P., Dickinson C.M. Amodiaquine as a prodrug. importance of metabolite(s) in the antimalarial effect of amodiaquine in humans Life Sci. 36:1985;53-62.
66. Ciak J., Hahn F.E. Chloroquine. mode of action Science. 151:1966;347-349.
67. Clark I.A., Hunt N.H. Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria. Infect. Immun. 39:1983;1-6.
68. Clark I.A., Hunt N.H., Cowden W.B., Maxwell L.E., Mackie E.J. Radical-mediated damage to parasites and erythrocytes in Plasmodium vinckei infected mice after injection of t-butyl hydroperoxide. Clin. Exp. Immunol. 56:1984;524-530.
69. Clarke J.B., Maggs J.L., Kitteringham N.R., Park B.K. Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91:1990;335-342.
70. Clarke J.B., Neftel K., Kitteringham N.R., Park B.K. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int. Arch. Allergy Appl. Immunol. 95:1991;369-375.
71. Coatney G.R. Pitfalls in a discovery. the chronicle of chloroquine Am. J. Trop. Med. Hyg. 12:1963;121-128.
72. Cohen S.N., Yielding K. Spectrophotometric studies of the interaction of chloroquine with deoxyribonucleic acid. J. Biol. Chem. 240:1965;3123-3131. a.
73. Cohen S.N., Yielding K. Inhibition of RNA and DNA polymerase reactions by chloroquine. Proc. Natl. Acad. Sci. USA. 54:1965;521-527. b.
74. Cohen S.N., Phifer K.O., Yielding K. Complex formation between chloroquine and ferrihaemic acid in vitro, and its effect on the antimalarial action of chloroquine. Nature. 202:1964;805-806.
75. Coleman R.E., Nath A.K., Schneider I., Song G.H., Klein T.A., Milhous W.K. Prevention of sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes by transmission-blocking antimalarials. Am. J. Trop. Med. Hyg. 50:1994;646-653.
76. Collins W.E., Jeffery G.M. Primaquine resistance in Plasmodium vivax. Am. J. Trop. Med. Hyg. 55:1996;243-249.
77. Colwell W.T., Brown V., Christie P., Lange J., Yamamoto K., Henery D.W. Antimalarial arylaminopropanols. J. Med. Chem. 15:1972;771-774.
78. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:1989;695-698.
79. Cowman A.F. Mechanism of drug resistance in malaria. Aust. N. Z. J. Med. 25:1995;837-844.
80. Cowman A.F., Karcz S., Galatis D., Culvenor J.G. A P-glycoprotein homolog of Plasmodium falciparum is localized on the digestive vacuole. J. Cell Biol. 113:1991;1033-1042.
81. Cowman A.F., Galatis D., Thompson J.K. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. USA. 91:1994;1143-1147.
82. Cowman A.F., Deady L.W., Deharo E., Desneves J., Tilley L. Synthesis and activity of some antimalarial bisquinolinemethanols. Aust. J. Chem. 50:1997;1091-1096.
83. Davis M.J., Woolf A.D. Role of antimalarials in rheumatoid arthritis - the British experience. Lupus. 5(Suppl. 1):1996;S37-S40.
84. De D., Krogstad F.M., Cogswell F.B., Krogstad D.J. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 55:1996;579-583.
85. De Duve C., De Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Lysosomotrophic agents. Biochem. Pharmacol. 23:1974;2495-2531.
86. Desjardins R.E., Pamplin C.L., von Bredow J., Barry K.G., Canfield C.J. Kinetics of a new antimalarial, mefloquine. Clin. Pharmacol. Ther. 26:1979;372-379.
87. Desneves J., Thorn G., Berman A., Galatis D., La Greca N., Sinding J., Foley M., Deady L.W., Cowman A.F., Tilley L. Photoaffinity labelling of mefloquine-binding proteins in human serum, uninfected erythrocytes and Plasmodium falciparum-infected erythrocytes. Mol. Biochem. Parasitol. 82:1996;181-194.
88. de Vries E., Stam J.G., Franssen F.F., van der Vliet P.C., Overdulve J.P. Purification and characterization of DNA polymerases from Plasmodium berghei. Mol. Biochem. Parasitol. 45:1991;223-232.
89. Dockrell H.M., Playfair J.H. Killing of blood-stage murine malaria parasites by hydrogen peroxide. Infect. Immun. 39:1983;456-459.
90. Dorn A., Stoffel R., Matile H., Bubendorf A., Ridely R.G. Malarial haemozoin/β-haematin supports haem polymerisation in the absence of protein. Nature. 374:1995;269-271.
91. Draper C.C., Brubaker G., Geser A., Kilimali V.A., Wernsdorfer W.H. Serial studies on the evolution of chloroquine resistance in an area of East Africa receiving intermittent malaria chemosuppression. Bull. WHO. 63:1985;109-118.
92. Draper C.C., Hills M., Kilimali V.A., Brubaker G. Serial studies on the evolution of drug resistance in malaria in an area of east Africa. findings from 1979 up to 1986 J. Trop. Med. Hyg. 91:1988;265-273.
93. Dubois V.L., Platel D.F., Pauly G., Tribouley-Duret J. Plasmodium berghei. implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo Exp. Parasitol. 81:1995;117-124.
94. Dutta P., Fitch C.D. Diverse membrane-active agents modify the hemolytic response to ferriprotoporphyrin IX. J. Pharmacol. Exp. Ther. 225:1983;729-734.
95. Egan T.J., Ross D.C., Adams P.A. Quinoline antimalarial drugs inhibit spontaneous formation of β-haematin (malaria pigment). FEBS Lett. 352:1994;54-57.
96. Ekweozor C., Aderounmu A.F., Sodeinde O. Comparison of the relative in vitro activity of chloroquine and amodiaquine against chloroquine-sensitive strains of P. falciparum. Ann. Trop. Med. Parasitol. 81:1987;95-99.
97. El-Shoura S.M. Falciparum malaria in naturally infected human patients. VIII. Fine structure of intraerythrocytic asexual forms before and during chloroquine treatment Appl. Parasitol. 35:1994;207-218.
98. Elslager E.F., Tendick F.H., Werbel L.M. Repository drugs. VIII. Ester and amide congeners of amodiaquine, hydroxychloroquine, oxychloroquine, primaquine, quinacrine and related substances as potential long-acting antimalarial agents. J. Med. Chem. 12:1969;600-607.
99. Elueze E.I., Croft S.L., Warhurst D.C. Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. J. Antimicrob. Chemother. 37:1996;511-518.
100. Espinal C.A., Cortes G.T., Guerra P., Arias A.E. Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia. Am. J. Trop. Med. Hyg. 34:1985;675-680.
101. Eyles D.E., Hoo C.C., Warren McW., Sandosham A.A. Plasmodium falciparum resistant to chloroquine in Cambodia. Am. J. Trop. Med. Hyg. 12:1963;840-843.
102. Fairfield A.S., Meshnick S.R., Eaton J.W. Malaria parasites adopt host cell superoxide dismutase. Science. 221:1983;764-766.
103. Fairfield A.S., Abosch A., Ranz A., Eaton J.W., Meshnick S.R. Oxidant defense enzymes of Plasmodium falciparum. Mol. Biochem. Parasitol. 30:1988;77-82.
104. Fairley N.H. Chemotherapeutic suppression and prophylaxis in malaria. an experimental investigation undertaken by medical research teams in Australia Trans. Roy. Soc. Trop. Med. Hyg. 38:1945;311-365.
105. Ferrari V., Cutler D.J. Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane. Biochem. Pharmacol. 41:1991;23-30. a.
106. Ferrari V., Cutler D.J. Simulation of kinetic data on the influx and efflux of chloroquine by erythrocytes infected with Plasmodium falciparum. Evidence for a drug-importer in chloroquine-sensitive strains. Biochem. Pharmacol. 42:1991;S167-S179. b.
107. 14C-chloroquine Antimicrob. Agents Chemother. 3:1973;545-548.
108. Fitch C.D. Antimalarial schizonticides. ferriprotoporphyrin IX intercalation hypothesis Parasitol. Today. 2:1986;330-331.
109. Fitch C.D., Chou A.C. Heat-labile and heat-stimulable heme polymerase activities in Plasmodium berghei. Mol. Biochem. Parasitol. 82:1996;261-264.
110. Fitch C.D., Yunis N.G., Chevli R., Gonzales Y. High-affinity accumulation of chloroquine by mouse erythrocytes infected with Plasmodium berghii. J. Clin. Invest. 54:1974;24-33.
111. Fitch C.D., Chan R.L., Chevli R. Chloroquine resistance in malaria. accessibility of drug receptors to mefloquine Antimicrob. Agents Chemother. 15:1979;258-262.
112. Fletcher K.A., Barton P.F., Kelly J.A. Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem. Pharmacol. 37:1988;2683-2690.
113. Foley M., Tilley L. Home improvements. malaria and the red cell. A review Parasitol. Today. 11:1995;436-439.
114. Foley M., Tilley L. Quinoline antimalarials. mechanisms of action and resistance Int. J. Parasitol. 27:1997;231-240.
115. Foley M., Deady L.W., Ng K., Cowman A.F., Tilley L. Photoaffinity labelling of chloroquine-binding proteins in Plasmodium falciparum. J. Biol. Chem. 269:1994;6955-6961.
116. Fonseca L., Vigario A.M., Seixas E., do Rosario V.E. Plasmodium berghei. selection of mefloquine-resistant parasites through drug pressure in mosquitoes Exp. Parasitol. 81:1995;55-62.
117. Fontanet A.L., Johnston D.B., Walker A.M., Rooney W., Thimasarn K., Sturchler D., Macdonald M., Hours M., Wirth D.F. High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. Bull. WHO. 71:1993;377-383.
118. Foote S.J., Cowman A.F. The mode of action and mechanism of resistance to antimalarial drugs. Acta Trop. 56:1994;157-171.
119. Foote S.J., Thompson J.K., Cowman A.F., Kemp D.J. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 57:1989;921-930.
120. Foote S.J., Kyle D.E., Martin R.K., Oduola A.M.J., Forsyth K., Kemp D.J., Cowman A.F. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature. 345:1990;255-258.
121. Foster S.D. Pricing, distribution and use of antimalarial drugs. Bull. WHO. 69:1991;349-363.
122. Fox R. Anti-malarial drugs. possible mechanisms of action in autoimmune disease and prospects for drug development Lupus. 5:1996;S4-S10.
123. Freedman D.O. Imported malaria - here to stay. Am. J. Med. 93:1992;239-242.
124. Fridovich I. Biological effects of the superoxide radical. Arch. Biochem. Biophys. 247:1986;1-11.
125. Fries J.F., Williams C.A., Ramey D.R., Bloch D.A. The relative toxicity of alternative therapies for rheumatoid arthritis. implications for the therapeutic progression Semin. Arthritis Rheum. 23:1993;68-73.
126. Fry M., Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43:1992;1545-1553.
127. Fu S., Xiao S.-H. Pryonaridine. a new antimalarial drug Parasitol.Today. 7:1991;310-313.
128. Furst D.E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 5:1996;S11-S15.
129. Gabay T., Krugliak M., Shalmaeiv G., Ginsburg H. Inhibition by antimalarial drugs of haemoglobin denaturation and iron release in acidified erythrocytes. possible mechanism of their antimalarial effect Parasitology. 108:1994;371-381.
130. Gamain B., Langsley G., Fourmaux M.N., Touzel J.P., Camus D., Dive D., Slomianny C. Molecular characterization of the glutathione peroxidase gene of the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 78:1996;237-248.
131. Garavelli P.L., Corti E. Chloroquine resistance in Plasmodium vivax. the first case in Brazil Trans R. Soc. Trop. Med. Hyg. 86:1992;128.
132. Gay F., Bustos D.G., Diquet B., Rivero L.R., Litaudon M., Pichet C., Danis M., Gentilini M. Cross-resistance between mefloquine and halofantrine. Lancet. 336:1990;1262.
133. Geary T.G., Jensen J.B. Lack of cross-resistance to 4-aminoquinolines in chloroquine-resistant Plasmodium falciparum in vitro. J. Parasitol. 69:1983;97-105.
134. Geary T.G., Bonanni L.C., Jensen J.B., Ginsburg H. Effects of combinations of quinoline-containing antimalarials on Plasmodium falciparum in culture. Ann. Trop. Med. Parasitol. 80:1986;285-291. a.
135. Geary T.G., Jensen J.B., Ginsburg H. Uptake of [3H]chloroquine by drug-sensitive and -resistant strains of the human malaria parasite Plasmodium falciparum. Biochem. Pharmacol. 35:1986;3805-3812. b.
136. Geary T.G., Divo A.D., Jensen J.B., Zangwill M., Ginsburg H. Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Implications for mechanism of action of and resistance to the drug. Biochem. Pharmacol. 40:1990;685-691.
137. Giboda M., Denis M.B. Response of Kampuchean strains of Plasmodium falciparum to antimalarials. in vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro J. Trop. Med. Hyg. 91:1988;205-211.
138. Ginsburg H., Krugliak M. Quinoline-containing antimalarials mode of action. drug resistance and its reversal Biochem. Pharmacol. 43:1992;63-70.
139. Ginsburg H., Stein W.D. Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes. Assessment of the factors that may determine drug resistance. Biochem. Pharmacol. 41:1991;1463-1470.
140. Ginsburg H., Nissani E., Krugliak M. Alkalinisation of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity. Biochem. Pharmacol. 38:1989;2645-2654.
141. Goldberg D.E., Slater A.F.G. The pathway of hemoglobin degradation in malaria parasites. Parasitol. Today. 8:1992;280-283.
142. Goldberg D.E., Slater A.F.G., Cerami A., Henderson G.B. Haemoglobin degradation in the malaria parasite Plasmodium falciparum. an ordered process in a unique organelle Proc. Natl. Acad. Sci. USA. 87:1990;2931-2935.
143. Goldberg D.E., Sharma V., Oksman A., Gluzman I.Y., Wellems T.E., Piwnica-Worms D. Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes. J. Biol. Chem. 272:1997;6567-6572.
144. Gonzalez-Noriega A., Grubb J.H., Talkad V., Sly W.S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J. Cell Biol. 85:1980;839-852.
145. Good M.I., Shader R.I. Lethality and behavioral side effects of chloroquine. J. Clin. Psychopharmacol. 2:1982;40-47.
146. Gottesman M.M., Pastan I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263:1988;12163-12166.
147. Grau G.E., De Kossodo S. Cerebral malaria. mediators, mechanical obstruction or more? Parasitol.Today. 10:1994;408-409.
148. Green M.D., Xiao L., Lal A.A. Formation of hydroxyeicosatetraenoic acids from hemozoin-catalyzed oxidation of arachidonic acid. Mol. Biochem. Parasitol. 83:1996;183-188.
149. Greenwood D. Conflicts of interest. the genesis of synthetic antimalarial agents in peace and war J. Antimicrob. Chemother. 36:1995;857-872.
150. Grellier P., Rigomier D., Clavey V., Fruchart J.-C., Schrevel J. Lipid traffic between high density lipoproteins and Plasmodium falciparum-infected red blood cells. J. Cell Biol. 112:1991;267-277.
151. Guerra F. The introduction of Cinchona in the treatment of malaria. J. Trop. Med. Hyg. 80:1977;135-140.
152. Hahn F.E., O'Brien R.L., Ciak J., Allison J.L., Olenick J.G. Studies on the mode of action of chloroquine and quinine and on chloroquine resistance. Mil. Med. 131(Suppl. 9):1966;1071-1089.
153. Haines A., Epstein P.R., McMichael A.J. Global health watch. monitoring impacts of environmental change Lancet. 342:1993;1464-1469.
154. Hall A.P. Quinine by intravenous infusion for falciparum malaria. Br. Med. J. 285:1982;439.
155. Hall A.P., Czerwinski A.W., Madonia E.C., Evensen K.L. Human plasma and urine quinine levels following tablets, capsules, and intravenous infusion. Clin. Pharmacol. Ther. 14:1973;580-585.
156. Har-El R., Marva E., Chevion M., Golenser J. Is hemin responsible for the susceptibility of Plasmodia to oxidant stress? Free Radical Res. Commun. 18:1993;279-290.
157. Harinasuta T., Suntharasamai P., Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet ii: 657-660:1965.
158. Harrison A.C., Kitteringham N.R., Clarke J.B., Park B.K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43:1992;1421-1430.
159. Hatton C.S., Peto T.E., Bunch C., Pasvol G., Russell S.J., Singer C.R., Edwards G., Winstanley P. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet i: 411-414:1986.
160. Hawley S.R., Bray P.G., O'Neill P.M., Naisbitt D.J., Park B.K., Ward S.A. Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Antimicrob. Agents Chemother. 40:1996;2345-2349. a.
161. Hawley S.R., Bray P.G., O'Neill P.M., Park B.K., Ward S.A. The role of drug accumulation in 4-aminoquinoline antimalarial potency. The influence of structural substitution and physicochemical properties. Biochem. Pharmacol. 52:1996;723-733. b.
162. Hawley S., Bray P., Park K., Ward S. Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol. Biochem. Parasitol. 80:1996;15-25. c.
163. Hellerstein S., Spees W., Surapathana L.O. Hemoglobin concentration and erythrocyte cation content. J. Lab. Clin. Med. 76:1970;10-24.
164. Hennequin C., Bourée P., Bazin N., Bisaro F., Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch. Int. Med. 154:1994;2360-2362.
165. Hofheinz, W. and Masciadri, R. (1995) Bisquinolines for the treatment of malaria. International Patent Application PCT/EP95/02052.
166. Hofheinz W., Merkli B. Quinine and quinine analogues. Peters W., Richards W.H.G. Antimalarial Drugs II. 1984;61-81 Springer Verlag, Berlin.
167. Homewood C.A., Warhurst D.C., Peters W., Baggaley V.C. Lysosomes, pH and the antimalarial action of chloroquine. Nature. 235:1972;50-52.
168. Hunt N.H., Stocker R. Oxidative stress and the redox status of malaria-infected erythrocytes. Blood Cells. 16:1990;499-526.
169. Ignatushchenko M.V., Winter R.W., Bachinger H.P., Hinrichs D.J., Riscoe M.K. Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett. 409:1997;67-73.
170. Ismail F.M., Dascombe M.J., Carr P., North S.E. An exploration of the structure-activity relationships of 4-aminoquinolines. novel antimalarials with activity in-vivo J. Pharm. Pharmacol. 48:1996;841-850.
171. Jacobs G.H., Aikawa M., Milhous W.K., Rabbege J.R. An ultrastructural study of the effects of mefloquine on malaria parasites. Am. J. Trop. Med. Hyg. 36:1987;9-14.
172. Kain K.C. Chemotherapy and prevention of drug-resistant malaria. Wilderness Environ. Med. 6:1995;307-324.
173. Karbwang J., White N.J. Clinical pharmacokinetics of mefloquine. Clin. Pharmacokinet. 19:1990;264-279.
174. Karcz S.R., Galatis D., Cowman A.F. Nucleotide binding properties of a P-glycoprotein homologue from Plasmodium falciparum. Mol. Biochem. Parasitol. 58:1993;269-276. a.
175. Karcz S.R., Herrmann V.R., Cowman A.F. Cloning and characterization of a vacuolar ATPase A subunit homologue from Plasmodium falciparum. Mol. Biochem. Parasitol. 58:1993;333-344. b.
176. Karcz S.R., Herrmann V.R., Trottein F., Cowman A.F. Cloning and characterization of the vacuolar ATPase B subunit from Plasmodium falciparum. Mol. Biochem. Parasitol. 65:1994;123-133.
177. Karle J.M., Karle I.L. Crystal structure and molecular structure of mefloquine methylsulfonate monohydrate. implications for a malaria receptor Antimicrob. Agents Chemother. 35:1991;2238-2245.
178. Kelly J.C., Wasserman G.S., Bernard W.D., Schultz C., Knapp J. Chloroquine poisoning in a child. Ann. Emerg. Med. 19:1990;47-50.
179. Khraishi M.M., Singh G. The role of anti-malarials in rheumatoid arthritis - the American experience. Lupus. 5(Suppl. 1):1996;S41-S44.
180. Kihamia C.M., Gill H.S. Chloroquine-resistant falciparum malaria in semi-immune African Tanzaniana. Lancet ii: 43:1982.
181. Knowles G., Davidson W.L., Jolley D., Alpers M.P. The relationship between the in vitro response of Plasmodium falciparum to chloroquine, quinine and mefloquine. Trans. R. Soc. Trop. Med. Hyg. 78:1984;146-150.
182. Koh H.L., Go M.L., Ngiam T.L., Mak J.W. Conformational and structural features determining in vitro antimalarial activity of some indolo[3,2-c]quinolines, anilinoquinolines and tetrahydroindolo[3,2-d] benzazepeines. Eur. J. Med. Chem. 29:1994;107-113.
183. Kotecka B.M., Barlin G.B., Edstein M.D., Rieckmann K.H. New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine. Antimicrob. Agents Chemother. 41:1997;1369-1374.
184. Kremsner P.G., Winkler S., Brandts C., Neifer S., Bienzle U., Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J. Infect. Dis. 169:1994;467-470.
185. Kremsner P.G., Luty A.J.F., Granger W. Combination chemotherapy for Plasmodium falciparum malaria. Parasitol. Today. 13:1997;167-168.
186. Krogstad D.J., Schlesinger P.H. A perspective on antimalarial action. effects of weak bases on Plasmodium falciparum Biochem. Pharmacol. 35:1986;547-552.
187. Krogstad D.J., Schlesinger P.H., Gluzman I.Y. Antimalarials increase vesicle pH in Plasmodium falciparum. J. Cell Biol. 101:1985;2301-2309.
188. Krogstad D.J., Gluzman I.Y., Kyle D.E., Oduola A.M., Martin S.K., Milhous
189. Krogstad D.J., Gluzman I.Y., Herwaldt B.L., Schlesinger P.H., Wellems T.E. Energy dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum. Biochem. Pharmacol. 43:1992;57-62.
190. Kubo M., Hostetler K.Y. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry. 24:1985;6515-6520.
191. Kwiatkowski D., Hill A.V., Sambou I., Twumasi P., Castracane J., Manogue K.R., Cerami A., Brewster D.R., Greenwood B.M. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 336:1990;1201-1204.
192. Kyle D.E., Milhous W.K., Rossan R.N. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. Am. J. Trop. Med. Hyg. 48:1993;126-133.
193. Lambros C., Notsch J.D. Plasmodium falciparum. mefloquine resistance produced in vitro. Bull. WHO. 62:1984;433-438.
194. Langreth S.G., Nguyen-Dinh P., Trager W. Plasmodium falciparum. merozoite invasion in vitro in the presence of chloroquine Exp. Parasitol. 46:1978;235-238.
195. Le Bras J., Deloron P., Charmot G. Dichlorquinazine (alpha 4-aminoquinoline) effective in vitro against chloroquine-resistant Plasmodium falciparum. Lancet i: 73-74:1983;. a.
196. Le Bras J., Deloron P., Ricour A., Andrieu B., Savel J., Couland J.P. Plasmodium falciparum. drug sensitivity in vitro of isolates before and after adaptation to continuous culture Exp. Parasitol. 56:1983;9-14. b.
197. Levy M.R., Siddiqui W.A., Chou S.C. Acid protease activity in Plasmodium falciparum and P. knowlesi and ghosts of their respective host red cells. Nature. 247:1974;546-549.
198. Li Y.T., Hu Y.G., Huang H.Z., Zhu D.Q., Huang W.J., Wu D.L., Qian Y.L. Hydroxypiperaquine phosphate in treatment of falciparum malaria. Chin. Med. J. 94:1981;301-302.
199. Lim A.S., Galatis D., Cowman A.F. Plasmodium falciparum. amplification and overexpression of pfmdr1 is not necessary for increased mefloquine resistance Exp. Parasitol. 83:1996;295-303.
200. Loeb R.F., Clarke W.M., Coateney G.R., Coggeshall L.T., Dieuaide F.R., Dochez A.R., Hakansson E.G., Marshall E.K., Marvel S.C., McCoy O.R., Sapero J.J., Serbell W.H., Shannon J.A., Carden G.A. Activity of a new antimalarial agent, chloroquine (SN 7618). J. Am. Med. Assoc. 130:1946;1069-1070.
201. Loevinsohn M.E. Climatic warming and increased malaria incidence in Rwanda. Lancet. 343:1994;714-718.
202. Looareesuwan S., White N.J., Chanthavanich P., Edwards G., Nicholl D.D., Bunch C., Warrell D.A. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br. J. Clin. Pharmacol. 22:1986;31-36.
203. Looareesuwan S., Viravan C., Vanijanonta S., Wilairatana P., Suntharasamai P., Charoenlarp P., Arnold K., Kyle D., Canfield C., Webster K. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet. 339:1992;821-824.
204. Luzzi G.A., Peto T.E. Adverse effects of antimalarials. An update. Drug Saf. 8:1993;295-311.
205. MacIntyre A.C., Cutler D.J. In vitro binding of chloroquine to rat muscle preparations. J. Pharm. Sci. 75:1986;1068-1070.
206. Mackerras M.J., Ercole Q.N. Observations on the action of quinine, atebrine and plasmoquine on the gametocytes of Plasmodium falciparum. Trans. Soc. Trop. Med. Hyg. 42:1949;443-454.
207. Macomber P.B., Sprinz H. Morphological effects of chloroquine on Plasmodium berghei in mice. Nature. 214:1967;937-939.
208. Macomber P.B., O'Brien R.L., Hahn F.E. Chloroquine. physiological basis of drug resistance in Plasmodium berghei Science. 152:1966;1374-1375.
209. Maggs J.L., Tingle M.D., Kitteringham N.R., Park B.K. Drug-protein conjugates - XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem. Pharmacol. 37:1988;303-311.
210. Mahoney J., Eaton J.W. Chloroquine resistant malaria. association with enhanced plasmodial protease activity Biochem. Biophys. Res. Commun. 100:1981;1266-1271.
211. Maitland K., Williams T.N., Kotecka B.M., Edstein M.D., Rieckmann K.H. Plasma chloroquine concentrations in young and older malaria patients treated with chloroquine. Acta Trop. 66:1997;155-161.
212. Malhotra K., Salmon D., Le Bras J., Vilde J.L. Potentiation of chloroquine activity against Plasmodium falciparum by the peroxidase-hydrogen peroxide system. Antimicrob. Agents Chemother. 34:1990;1981-1985.
213. Martin S.K. Chloroquine-resistant Plasmodium falciparum and the MDR phenotype. Parasitol. Today. 9:1993;278-280.
214. Martin S.K., Oduola A.M.J., Milhous W.K. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science. 235:1987;899-901.
215. Martiney J.A., Cerami A., Slater A.F. Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J. Biol. Chem. 270:1995;22393-22398.
216. Martiney J.A., Cerami A., Slater A.F. Inhibition of hemozoin formation in Plasmodium falciparum trophozoite extracts by heme analogs. possible implication in the resistance to malaria conferred by the β-thalassemia trait Mol. Med. 2:1996;236-246.
217. Mathews S.T., Selvam R. Effect of radical treatment on erythrocyte lipid peroxidation in Plasmodium vivax-infected malaria patients. Biochem. Int. 25:1991;211-220.
218. Matson P.A., Luby S.P., Redd S.C., Rolka H.R., Meriwether R.A. Cardiac effects of standard-dose halofantrine therapy. Am. J. Trop. Med. Hyg. 54:1996;229-231.
219. McChesney E.W., Fitch C.D. 4-Aminoquinolines. Peters W., Richards W.H.G. Antimalarial Drugs II. Current Antimalarials and New Drug Developments:1984;30-60 Springer-Verlag, Berlin, Heidelberg.
220. McChesney E.W., Conway W.D., Banks W.F. Jr., Rogers J.E., Shekosky J.M. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J. Pharmacol. Exp. Ther. 151:1966;482-493.
221. McKerrow J.H., Sun E., Rosenthal P.J., Bouvier J. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol. 47:1993;821-853.
222. Meinâo I.M., Sato E.I., Andrade L.E., Ferraz M.B., Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 5:1996;237-241.
223. Menting J.G.T., Tilley L., Deady L.W., Ng K., Cowman A.F., Foley M. The antimalarial drug, chloroquine, interacts specifically with lactate dehydrogenase from Plasmodium falciparum. Mol. Biochem. Parasitol. 88:1997;215-224.
224. Merkli B., Richle R.W. Studies on the resistance to single and combined antimalarials in the Plasmodium berghei mouse model. Acta Trop. 37:1980;228-231.
225. Meshnick S.R. Is haemozoin a target for antimalarial drugs? Ann. Trop. Med. Parasitol. 90:1996;367-372.
226. Meshnick S.R. Why does quinine still work after 350 years of use? Parasitol. Today. 13:1997;89-90.
227. Meshnick S.R., Marr J.J. Intracellular parasites. New developments in chemotherapy. Subcell. Biochem. 18:1992;401-441.
228. Meshnick S.R., Chang K.P., Cerami A. Heme lysis of the bloodstream forms of Trypanosoma brucei. Biochem. Pharmacol. 26:1977;1923-1928.
229. Meshnick S.R., Taylor T.E., Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides. from herbal remedy to targeted chemotherapy Microbiol. Rev. 60:1996;301-315.
230. Mockenhaupt F.P. Mefloquine resistance in Plasmodium falciparum. Parasitol. Today. 11:1995;248-253.
231. Mohan K., Dubey M.L., Ganguly N.K., Mahajan R.C. Plasmodium falciparum-induced perturbations of the erythrocyte antioxidant system. Clin. Chim. Acta. 209:1992;19-26. a.
232. Mohan K., Ganguly N.K., Dubey M.L., Mahajan R.C. Oxidative damage of erythrocytes infected with Plasmodium falciparum. An in vitro study. Ann. Hematol. 65:1992;131-134. b.
233. Molyneux M., Fox R. Diagnosis and treatment of malaria in Britain. Br. Med. J. 306:1993;1175-1180.
234. Monlun E., Pillet O., Cochard J.F., Favarel Garrigues J.C., Le Bras M. Prolonged QT interval with halofantrine. Lancet. 341:1993;1541-1542.
235. Moreau S., Perly B., Biguet J. Interaction of chloroquine with ferriprotophorphyrin IX. Nuclear magnetic resonance study. Biochimie. 64:1982;1015-1025.
236. Mu J.Y., Israili Z.H., Dayton P.G. Studies of the disposition and metabolism of mefloquine HCl (WR 142, 490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR. 30,090.(Drug Metab. Dispos. 3):1975;198-210.
237. Myat-Phone-Kyaw Myint-Oo, Myint-Lwin Thaw-Zin, Kyin-Hla-Aye and Nwe-Nwe-Yin Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans. R. Soc. Trop. Med. Hyg. 87:1993;687.
238. Na-Bangchang K., Limpaibul L., Thanavibul A., Tan-Ariya P., Karbwang J. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 38:1994;278-281.
239. Naor Z., Catt K.J. Mechanism of action of gonadotropin-releasing hormone. Involvement of phospholipid turnover in luteinizing hormone release. J. Biol. Chem. 256:1981;2226-2229.
240. Nateghpour M., Ward S.A., Howells R.E. Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum. Antimicrob. Agents Chemother. 37:1993;2337-2343.
241. Navarro M., Perez H., Sanchez-Delgado R.A. Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6. J. Med. Chem. 40:1997;1937-1939.
242. Neftel K.A., Woodtly W., Schmid M., Frick P.G., Fehr J. Amodiaquine induced agranulocytosis and liver damage Br. Med. J. 292:1986;721-723.
243. + exchanger isoforms. Am. J. Physiol. 268:1995;C283-C296.
244. Nosten F., Price R.N. New antimalarials. A risk-benefit analysis. Drug Saf. 12:1995;264-273.
245. Nosten F., ter Kuile F., Chongsuphajaisiddhi T., Luxemburger C., Webster H.K., Edstein M., Phaipun L., Thew K.L., White N.J. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 337:1991;1140-1143.
246. Obaldia N., Rossan R.N., Cooper R.D., Kyle D.E., Nuzum E.O., Rieckmann K.H., Shanks G.D. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am. J. Trop. Med. Hyg. 56:1997;508-510.
247. Ockenhouse C.F., Schulman S., Shear H.L. Induction of crisis forms in the human malaria parasite Plasmodium falciparum by gamma-interferon-activated, monocyte-derived macrophages. J. Immunol. 133:1984;1601-1608.
248. Oduola A.M., Milhous W.K., Weatherly N.F., Bowdre J.H., Desjardins R.E. Plasmodium falciparum. induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro Exp. Parasitol. 67:1988;354-360.
249. Oduola A.M.J., Omitowoju G.O., Gerena L., Kyle D.E., Milhous W.K., Sowunmi A., Salako L.A. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. Trans. R. Soc. Trop. Med. Hyg. 87:1992;81-83. a.
250. Oduola A.M.J., Sowunmi A., Milhous W.K., Kyle D.E., Martin R.K., Walker O., Salako L.A. Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans. R. Soc. Trop. Med. Hyg. 86:1992;123-126. b.
251. Ohnmacht C.J., Patel A.R., Lutz R.E. Antimalarials. 7. Bis(trifluoromethyl)-(. 2-piperidyl)-4-quinolinemethanols.(J. Med. Chem. 14):1971;926-928.
252. Ohsawa K., Tanabe K., Kimata I., Miki A. Ultrastructural changes associated with reversal of chloroquine resistance by verapamil in Plasmodium chabaudi. Parasitology. 103:1991;185-189.
253. Olatunde A., Obih P.O. Use and misuse of 4-aminoquinoline antimalarials in tropical Africa and re-examination of itch reaction to these drugs. Trop. Doct. 11:1981;97-101.
254. Olliaro P.L., Goldberg D.E. The Plasmodium digestive vacuole. metabolic headquarters and choice drug target Parasitol. Today. 11:1995;294-297.
255. Olliaro P.L., Trigg P.I. Status of antimalarial drugs under development. Bull. WHO. 73:1995;565-571.
256. Olliaro P.L., Castelli F., Caligaris S., Druilhe P., Carosi G. Ultrastructure of Plasmodium falciparum in vitro. II. Morphological patterns of different quinolines effects. Microbiologica. 12:1989;15-28.
257. Olliaro P.L., Nevill C., LeBras J., Ringwald P., Mussano P., Garner P., Brasseur P. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet. 348:1996;1196-1201.
258. O'Neill P.M., Harrison A.C., Storr R.C., Hawley S.R., Ward S.A., Park B.K. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. J. Med. Chem. 37:1994;1362-1370.
259. O'Neill P.M., Willock D.J., Hawley S.R., Bray P.G., Storr R.C., Ward S.A., Park B.K. Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues. J. Med. Chem. 40:1997;437-448.
260. Orjih A.U., Banyal H.S., Chelvi R., Fitch C.D. Hemin lyses malarial parasites. Science. 214:1981;667-669.
261. Palmer K.J., Holliday S.M., Brogden R.N. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 45:1993;430-475.
262. Pandey A.V., Tekwani B.L. Formation of haemozoin/beta-haematin under physiological conditions is not spontaneous. FEBS Lett. 393:1996;189-193.
263. Pandey A.V., Tekwani B.L. Depolymerisation of malarial hemozoin. a novel reaction initiated by blood schizonticidal antimalarials FEBS Lett. 402:1997;236-240.
264. Pandey A.V., Tekwani B.L., Pandey V.C. Characterisation of hemozoin from liver and spleen of mice infected with Plasmodium yoelii, a rodent malaria parasite. Biomed. Res. 16:1995;115-120.
265. Parker F.S., Irvin J.L. The interaction of chloroquine with nucleic acids and nucleoproteins. J. Biol. Chem. 199:1952;897-909.
266. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol. Today. 4:1988;112-115.
267. Peel S.A., Merritt S.C., Handy J., Baric R.S. Derivation of highly mefloquine-resistant lines from Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 48:1993;385-397.
268. Peel S.A., Bright P., Yount B., Handy J., Baric R.S. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 51:1994;648-658.
269. Perrin D.D. Dissociation Constants of Organic Bases in Aqueous Solution. 1965;Butterworth & Co, London.
270. Peters W. Morphological and physiological variations in chloroquine-resistant Plasmodium berghei. Ann. Soc. Belg. Med. Trop. 45:1965;365-378.
271. Peters W. Chemotherapy and Drug Resistance in Malaria. 1970;Academic Press, London.
272. Peters W. Chemotherapy and Drug Resistance in Malaria. 1987;Academic Press, London.
273. Peters W., Robinson B.L. The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent Plasmodium. Ann. Trop. Med. Parasitol. 85:1991;5-10.
274. Peters W., Howells R.E., Portus J., Robinson B.L., Thomas S., Warhurst D.C. The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR. 142,490).(Ann. Trop. Med. Parasitol. 71):1977;407-418.
275. Peters W., Robinson B.L., Milhous W.K. The chemotherapy of rodent malaria. LI. Studies on a new. 8-aminoquinoline,(WR 238,605. Ann. Trop. Med. Parasitol. 87):1993;547-552.
276. Peters W., Robinson B.L., Mittelholzer M.L., Crevoisier C., Sturchler D. The chemotherapy of rodent malaria. LII. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomers. Ann Trop. Med. Parasitol. 89:1995;465-468.
277. Phillips R.E., Looareesuwan S., Molyneux M.E., Hatz C., Warrell D.A. Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria. treatment with Sandostatin Q. J. Med. 86:1993;233-240.
278. Phillips-Howard P.A., Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf. 14:1996;131-145.
279. Picot S., Peyron F., Donadille A., Vuillez J.P., Barbe G., Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology. 80:1993;127-133.
280. Picot S., Nkwelle Akede A., Chaulet J.F., Tetanye E., Ringwald P., Prevesto J.M., Boudin C., Ambroise-Thomas P. Chloroquine self-treatment and clinical outcome of cerebral malaria in children. Clin. Exp. Immunol. 108:1997;279-283.
281. Plowe C.V., Wellems T.E. Molecular approaches to the spreading of drug resistant malaria. Jungkind D.L. Antimicrobial Resistance. A Crisis in Health Care:1995;197-209 Plenum Press, New York.
282. Polet H., Barr C.F. Chloroquine and dihydroquinine. In vitro studies of their antimalarial effect upon Plasmodium knowlesi. J. Pharmacol. Exp. Ther. 164:1968;380-386.
283. Price R.N., Nosten F., Luxemburger C., Kham A., Brockman A., Chongsuphajaisiddhi T., White N.J. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 89:1995;523-527.
284. Pullman T.N.K., Eichelberger L., Alving A.S., Jones R., Craige B., Whorton C.M. The use of SN-10,275 in the prophylaxis and treatment of sporozoite-induced vivax malaria (Chesson strain). J. Clin. Invest. 27:1948;12-16.
285. Raccurt C.P., Dumestre-Toulet V., Abraham E., Le Bras M., Brachet-Liermain A., Ripert C. Failure of falciparum malaria prophylaxis by mefloquine in travelers from West Africa. Am. J. Trop. Med. Hyg. 45:1991;319-324.
286. Ramkaran A.E., Peters W. Infectivity of chloroquine resistant Plasmodium berghei to Anopheles stephensi enhanced by chloroquine. Nature. 223:1969;635-636.
287. Ranz A., Meshnick S.R. Plasmodium falciparum. inhibitor sensitivity of the endogenous superoxide dismutase Exp. Parasitol. 69:1989;125-128.
288. Raynes K., Galatis D., Cowman A.F., Tilley L., Deady L.W. Synthesis and activity of some antimalarial bisquinolines. J. Med. Chem. 38:1995;204-206.
289. Raynes K., Foley M., Tilley L., Deady L. Novel bisquinoline antimalarials. synthesis, antimalarial activity and inhibition of haem polymerisation Biochem. Pharmacol. 52:1996;551-559.
290. Ribeiro, M. C. de A., Augusto, O. and Ferreira, A. M. da C. (1997) Influence of quinoline-containing antimalarials in the catalase activity of ferriprotoporphyrin IX. J. Inorg. Biochem. 65: 15-23.
291. Ridley R.G. Haemozoin formation in malaria parasites. is there a haem polymerase? Trends Microbiol. 4:1996;253-254.
292. Ridley R.G., White J.H., McAleese S.M., Goman M., Alano P., de Vries E., Kilbey B.J. DNA polymerase δ gene sequences from Plasmodium falciparum indicate that this enzyme is more highly conserved than DNA polymerase α Nucl. Acids Res. 19:1991;6731-6736.
293. Ridley R.G., Hofheinz W., Matile H., Jaquet C., Dorn A., Masciadri R., Jolidon S., Richter W.F., Guenzi A., Girometta M.A., Urwyler H., Huber W., Thaithong S., Peters W. 4-Aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrob. Agents Chemother. 40:1996;1846-1854.
294. Ridley R.G., Matile H., Jaquet C., Dorn A., Hofheinz W., Leupin W., Masciadri R., Theil F.P., Richter W.F., Girometta M.A., Guenzi A., Urwyler H., Gocke E., Potthast J.M., Csato M., Thomas A., Peters W. Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine. comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737 Antimicrob. Agents Chemother. 41:1997;677-686.
295. Riffkin C., Chung R., Wall D., Zalcberg J.R., Cowman A.F., Foley M., Tilley L. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem. Pharmacol. 52:1996;1545-1552.
296. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 316:1985;817-819.
297. Ritschel W.A., Hammer G.V., Thompson G.A. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int. J. Clin. Pharmacol. Biopharm. 16:1978;395-401.
298. Rosenthal P.J., Meshnick S.R. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol. 83:1996;131-139.
299. Rosenthal P.J., McKerrow J.H., Aikawa M., Nagasawa H., Leech J.H. A malarial cysteine proteinase is necessary for haemoglobin degradation by Plasmodium falciparum. J. Clin. Invest. 82:1988;1560-1566.
300. Roth E.F. Jr., Brotman D.S., Vanderberg J.P., Schulman S. Malarial pigment-dependent error in the estimation of hemoglobin content in Plasmodium falciparum-infected red cells. implications for metabolic and biochemical studies of the erythrocytic phases of malaria Am. J. Trop. Med. Hyg. 35:1986;906-911.
301. Rubin H., Salem J.S., Li L.S., Yang F.D., Mama S., Wang Z.M., Fisher A., Hamann C.S., Cooperman B.S. Cloning, sequence determination, and regulation of the ribonucleotide reductase subunits from Plasmodium falciparum. a target for antimalarial therapy Proc. Natl. Acad. Sci. USA. 90:1993;9280-9284.
302. Rubio J.P., Cowman A.F. Plasmodium falciparum. the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite Exp. Parasitol. 79:1994;137-147.
303. Rubio J.P., Cowman A.F. The ATP-binding cassette (ABC) gene family of Plasmodium falciparum. Parasitol. Today. 12:1996;135-140.
304. Ruetz S., Delling U., Brault M., Schurr E., Gros P. The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Proc. Natl. Acad. Sci. USA. 93:1996;9942-9947.
305. Rynes R.I. Ophthalmologic considerations in using antimalarials in the United States. Lupus. 5(Suppl. 1):1996;S73-S74.
306. Saggers V.H., Hariratnajothi N., McLean A.E. The effect of diet and phenobarbitone on quinine metabolism in the rat and in man. Biochem. Pharmacol. 19:1970;499-503.
307. Sanchez C.P., Wunsch S., Lanzer M. Identification of a chloroquine importer in Plasmodium falciparum. Differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. J. Biol. Chem. 272:1997;2652-2658.
308. Sando G.N., Titus-Dillon P., Hall C.W., Neufeld E.F. Inhibition of receptor-mediated uptake of a lysosomal enzyme into fibroblasts by chloroquine, procaine and ammonia. Exp. Cell. Res. 119:1979;359-364.
309. San George R.C., Nagel R.L., Farby M.E. On the mechanism of the red-cell accumulation of mefloquine, an antimalarial drug. Biochim. Biophys. Acta. 803:1984;174-181.
310. Schlagenhauf P., Steffen R., Lobel H., Johnson R., Letz R., Tschopp A., Vranjes N., Bergqvist Y., Ericsson O., Hellgren U., Rombo L., Mannino S., Handschin J., Sturchler D. Mefloquine tolerability during chemoprophylaxis. focus on adverse event assessments, stereochemistry and compliance Trop. Med. Int. Health. 1:1996;485-494.
311. Schlesinger P.H., Krogstad D.J., Herwaldt B.L. Antimalarial agents. mechanisms of action Antimicrob. Agents Chemother. 32:1988;793-798.
312. Schmidt L.H., Crosby R., Rasco J., Vaughan D. Antimalarial activities of various 4-quinolinemethanols with special attention to WR-142,490 (mefloquine). Antimicrob. Agents Chemother. 13:1978;1011-1030. a.
313. Schmidt L.H., Crosby R., Rasco J., Vaughan D. Antimalarial activities of various 9-phenanthrenemethanols with special attention to WR-122,455 and WR-171,669. Antimicrob. Agents Chemother. 14:1978;292-314. b.
314. Schmidt L.H., Crosby R., Rasco J., Vaughan D. Antimalarial activities of the 4-quinolinemethanols WR-184,806 and WR-226,253. Antimicrob. Agents Chemother. 14:1978;680-689. c.
315. Schueler F.W., Cantrell W.F. Antagonism of the antimalarial action of chloroquine by ferrihemate and an hypothesis for the mechanism of chloroquine resistance. J. Pharmacol. Exp. Ther. 143:1964;278-281.
316. Schuurkamp G.J., Spicer P.E., Kereu R.K., Bulungol P.K., Rieckmann K.H. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 86:1992;121-122.
317. Schwartz D.E., Eckert G., Hartmann D., Weber B., Richard-Lenoble D., Ekue J.M., Gentilini M. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy. 28:1982;70-84.
318. Scott H.V., Tan W.L., Barlin G.B. Antimalarial activity of Mannich bases derived from 4-(7′-bromo-1′,5′-naphthyridin-4′-ylamino)phenol and 4-(7′-trifluoromethylquinolin-4′-ylamino)phenol against Plasmodium falciparum in vitro. Ann. Trop. Med. Parasitol. 81:1987;85-93.
319. Scott H.V., Tan W.L., Barlin G.B. The in vitro and in vivo antimalarial activity of some Mannich bases derived from 4-[7′-bromo (and chloro)-1′,5′-naphthyridin-4′-ylamino]phenol and 4-(7′-trifluoromethylquinolin-4′-ylamino)phenol. Ann. Trop. Med. Parasitol. 82:1988;127-134.
320. Sinden R.E. Gametocytogenesis of Plasmodium falciparum in vitro. ultrastructural observations on the lethal action of chloroquine Ann. Trop. Med. Parasitol. 76:1982;15-23.
321. Singh T., Hoops J.F., Biel J.H., Hoya W.K., Stein R.G., Cruz D.R. Antimalarials. "Distal" hydrazine derivatives of 7-chloroquinoline. J. Med. Chem. 14:1971;532-535.
322. Slater A.F.G. Chloroquine. mechanism of drug action and resistance in Plasmodium falciparum Pharmacol. Ther. 57:1993;203-235.
323. Slater A.F.G., Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 355:1992;167-169.
324. Slater A.F.G., Swiggard W.J., Orton B.R., Flitter W.D., Goldberg D.E., Cerami A., Henderson G.B. An iron-carboxylate bond links the heme units of malarial parasite pigment. Proc. Natl. Acad. Sci. USA. 88:1991;325-329.
325. Sowunmi A., Oduola A.M., Ogundahunsi O.A., Falade C.O., Gbotosho G.O., Salako L.A. Enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in children. Trans. R. Soc. Trop. Med. Hyg. 91:1997;63-67.
326. Spalton D.J. Retinopathy and antimalarial drugs - the British experience. Lupus. 5(Suppl. 1):1996;S70-S72.
327. Speich R., Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N. Engl. J. Med. 331:1994;57-58.
328. Srivastava I.K., Rottenberg H., Vaidya A.B. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272:1997;3961-3966.
329. Srivastava P., Puri S.K., Dutta G.P., Pandey V.C. Status of oxidative stress and antioxidant defences during Plasmodium knowlesi infection and chloroquine treatment in Macaca mulatta. Int. J. Parasitol. 22:1992;243-245.
330. Steffen R., Fuchs E., Schildknecht J., Naef U., Funk M., Schlagenhauf P., Phillips-Howard P., Nevill C., Sturchler D. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 341:1993;1299-1303.
331. Strube R.E. The search for new antimalarial drugs. J. Trop. Med. Hyg. 78:1975;171-185.
332. Suebsaeng L., Wernsdorfer W.H., Rooney W. Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand. Bull. WHO. 64:1986;759-765.
333. Sugioka Y., Suzuki M. The chemical basis for the ferriprotoporphyrin IX-chloroquine complex induced lipid peroxidation. Biochim. Biophys. Acta. 1074:1991;19-24.
334. Sullivan A.D., Meshnick S.R. Haemozoin. identification and quantification Parasitol. Today. 12:1996;161-163.
335. Sullivan D.J., Gluzman I.Y., Goldberg D.E. Plasmodium hemozoin formation mediated by histidine-rich proteins. Science. 271:1996;219-222. a.
336. Sullivan D.J., Gluzman I.Y., Russell D.G., Goldberg D.E. On the molecular mechanism of chloroquine's antimalarial action. Proc. Natl. Acad. Sci. USA. 93:1996;11865-11870. b.
337. Sweeney T.R. Drugs with quinine-like action. Peters W., Richards W.H.G. Antimalarial Drugs II. Current Antimalarials and New Drug Developments:1984;267-313 Springer-Verlag, Berlin, Heidelberg.
338. Tabone M.D., Muanza K., Lyagoubi M., Jardel C., Pied S., Amedee-Manesme O., Grau G.E., Mazier D. The role of interleukin-6 in vitamin A deficiency during Plasmodium falciparum malaria and possible consequences for vitamin A supplementation. Immunology. 75:1992;553-554.
339. Tappel A.L. The mechanism of oxidation of unstaurated fatty acids by hematin compounds. Arch. Biochem. Biophys. 44:1953;378-395.
340. ter Kuile F.O., Nosten F., Thieren M., Luxemburgerer C., Edestein M.D., Chongsuphajaisiddhi T., Phaipun L., Webster H.K., White N.J. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J. Infect. Dis. 166:1992;1393-1400.
341. Thaithong S., Beale G.H., Chutmongkonkul M. Susceptibility of Plasmodium falciparum to five drugs. an in vitro study of isolates mainly from Thailand Trans. R. Soc. Trop. Med. Hyg. 77:1983;228-231.
342. Thelu J., Burnod J., Bracchi V., Ambroise-Thomas P. Identification of differentially transcribed RNA and DNA helicase-related genes of Plasmodium falciparum. DNA Cell Biol. 13:1994;1109-1115.
343. Thompson, P. E. and Werbel, L. M. (1972) Antimalarial Agents: Chemistry and Pharmacology, Destevens, G. (ed.) Academic Press New York.
344. Tin F., Hlaing N., Lasserre R. Single-dose treatment of falciparum malaria with mefloquine. field studies with different doses in semi-immune adults and children in Burma Bull. WHO. 60:1982;913-917.
345. Traylor T.G., Kim C., Richards J.L., Xu F., Perrin C.L. Reactions of iron (III) porphyrins with oxidants. Structure-reactivity studies. J. Am. Chem. Soc. 117:1995;3468-3474.
346. Trenholme C.M., Williams R.L., Desjardins R.E., Frischer H., Carson P.E., Rieckmann K.H., Canfield C.J. Mefloquine (WR 142,490) in the treatment of human malaria. Science. 190:1975;792-794.
347. Turner R.B., Woodward R.B. The chemistry of the cinchona. Manske R.H.F. The Alkaloids, Vol. III. 1953;181-223 Academic Press, New York.
348. Ullman B. Multidrug resistance and P-glycoproteins in parasitic protozoa. J. Bioenerg. Biomembr. 27:1995;77-84.
349. Unanue E. Antigen-presenting function of the macrophage. Annu. Rev. Immunol. 2:1984;395-428.
350. Vaidya A.B., Lashgari M.S., Pologe L.G., Morrisey J. Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol. Biochem. Parasitol. 58:1993;33-42.
351. Vander Jagt D.L., Hunsaker L.A., Campos N.M. Characterisation of haemoglobin degrading, low molecular weight protease from Plasmodium falciparum. Mol. Biochem. Parasitol. 18:1986;389-400.
352. Vanderkooi G., Prapunwattana P., Yuthavong Y. Evidence for electrogenic accumulation of mefloquine by malarial parasites. Biochem. Pharmacol. 37:1988;3623-3631.
353. van Es H.H.G., Karcz S., Chu F., Cowman A.F., Vidal S., Gros P., Schurr E. Expression of the plasmodial pfmdr1 gene in mammalian cells is associated with increased susceptibility to chloroquine. Mol. Cell. Biol. 14:1994;2419-2428. a.
354. van Es H.H., Renkema H., Aerts H., Schurr E. Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene. Mol. Biochem. Parasitol. 68:1994;209-219. b.
355. Vennerstrom, J. L. (1996) Bisquinolines and processes for their production and use to treat malaria. U.S. Patent No. 5,510,356.
356. Vennerstrom J.L., Eaton J.W. Oxidants, oxidant drugs, and malaria. J. Med. Chem. 31:1988;1269-1277.
357. Vennerstrom J.L., Ellis W.Y., Ager A.L., Andersen S.L., Gerena L., Milhous W.K. Bisquinolines. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria J. Med. Chem. 35:1992;2129-2134.
358. Verdier F., Le Bras J., Clavier F., Hatin I., Blayo M.C. Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob. Agents Chemother. 27:1985;561-564.
359. Vial H. Recent developments and rationale towards new strategies for malarial chemotherapy. Parasite. 3:1996;3-23.
360. Volkman S.K., Cowman A.F., Wirth D.F. Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA. 92:1995;8921-8925.
361. Wallace D.J. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus. a critical review Lupus. 5:1996;S59-S64.
362. Ward S.A. Mechanisms of chloroquine resistance in malarial chemotherapy. Trends Pharmacol. Sci. 91:1988;241-246.
363. Ward S.A., Bray P.G., Mungthin M., Hawley S.R. Current views on the mechanisms of resistance to quinoline-containing drugs in Plasmodium falciparum. Ann. Trop. Med. Parasitol. 89:1995;121-124.
364. Warhurst D.C. Chloroquine-resistant rodent malaria and the long-acting antimalarial 12,278 R. P. Trans. Roy. Soc. Trop. Med. Hyg. 60:1966;565-566.
365. Warhurst D.C. The quinine-haemin interaction and its relationship to antimalarial activity. Biochem. Pharmacol. 30:1981;3323-3327.
366. Warhurst D.C. Antimalarial schizontocides. why a permease is necessary Parasitol. Today. 4:1986;211-213.
367. Warhurst D.C. Haemozoin and the mode of action of blood schizontocides. more controversy Parasitol. Today. 11:1995;204-205.
368. Warhurst D.C., Hockley D.J. Mode of action of chloroquine on Plasmodium berghei and P. cynomolgi. Nature. 214:1967;935-936.
369. Warsame M., Wernsdorfer W.H., Bjorkman A. Lack of effect of desipramine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 86:1992;235-236.
370. Watt G., Long G.W., Grogl M., Martin S.K. Reversal of drug-resistant falciparum malaria by calcium antagonists. potential for host cell toxicity Trans. R. Soc. Trop. Med. Hyg. 84:1990;187-190.
371. Watt G., Loesuttivibool L., Shanks G.D., Bordreau E.F., Brown A.E., Pavanand K., Webster H.K., Wechgritaya S. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 47:1992;108-111.
372. Webster H.K., Boudreau E.F., Pavanand K., Yongvanitchit K., Pang L.W. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. Am. J. Trop. Med. Hyg. 34:1985;228-235. a.
373. Webster H.K., Thaithong S., Pavanand K., Yongvanitchit K., Pinswasdi C., Boudreau E.F. Cloning and characterization of mefloquine-resistant Plasmodium falciparum from Thailand. Am. J. Trop. Med. Hyg. 34:1985;1022-1027. b.
374. Weinke T., Trautmann M., Held T., Weber G., Eichenlaub D., Fleischer K., Kern W., Pohle H.D. Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Med. Hyg. 45:1991;86-91.
375. Weinke T., Held T., Trautmann M., Rogler G., Mravak S., Alexander M., Pohle H.D. Malaria therapy in 452 patients, with special reference to the use of quinine. J. Infect. 25:1992;173-180.
376. Wellems T.E., Panton L.J., Gluzman I.Y., Rosario V.E., Gwadz R.W., Walker-Jonah A., Krogstad D.J. Chloroquine resistance is not linked to mdr-like genes in a Plasmodium falciparum cross. Nature. 345:1990;253-255.
377. Wellems T.E., Walker-Jonah A., Panton L.J. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc. Natl. Acad. Sci. USA. 88:1991;3382-3386.
378. Werbel L.M., Cook P.D., Elslager E.F., Hung J.H., Johnson J.L., Kesten S.J., McNamara D.J., Ortwine D.F., Worth D.F. Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1′-biphenyl]-2-ols and N ω-oxides. J. Med. Chem. 29:1986;924-939.
379. Wetsteyn J.C., De Vries P.J., Oosterhuis B., Van Boxtel C.J. The pharmacokinetics of three multiple dose regimens of chloroquine. implications for malaria chemoprophylaxis Br. J. Clin. Pharmacol. 39:1995;696-699.
380. White J.H., Kilbey B.J., de Vries E., Goman M., Alano P., Cheesman S., McAleese S., Ridley R.G. The gene encoding DNA polymerase α from Plasmodium falciparum. Nucl. Acids Res. 21:1993;3643-3646.
381. White N.J. Clinical pharmacokinetics of antimalarial drugs. Clin. Pharmacokinet. 10:1985;187-215.
382. White N.J. Antimalarial pharmacokinetics and treatment regimens. Br. J. Clin. Pharmacol. 34:1992;1-10. a.
383. White N.J. Antimalarial drug resistance. the pace quickens J. Antimicrob. Chemother. 30:1992;571-585. b.
384. White N.J. Mefloquine in the prophylaxis and treatment of falciparum malaria. Br. Med. J. 308:1994;286-287.
385. White N.J., Olliaro P.L. Strategies for the prevention of antimalarial drug resistance. Parasitol.Today. 12:1996;399-401.
386. White N.J., Miller K.D., Churchill F.C., Berry C., Brown J., Williams S.B., Greenwood B.M. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N. Engl. J. Med. 319:1988;1493-1500.
387. Wilson C.M., Serrano A.E., Wasley A., Bogenschutz M.P., Shankar A.H., Wirth D.F. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science. 244:1989;1184-1186.
388. Wilson C.M., Volkman S.K., Thaithong S., Martin R.K., Kyle D.E., Milhous W.K., Wirth D.F. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in P. falciparum from Thailand. Mol. Biochem. Parasitol. 57:1993;151-160.
389. Wongsrichanalai C., Webster H.K., Wimonwattrawatee T., Sookto P., Chuanak N., Thimasarn K., Wernsdorfer W.H. Emergence of multidrug-resistant Plasmodium falciparum in Thailand. in vitro tracking Am. J. Trop. Med. Hyg. 47:1992;112-116. a.
390. Wongsrichanalai C., Webster H.K., Wimonwattrawatee T., Sookto P., Chuanak N., Timasarn K., Wernsdorfer W.H. In vitro sensitivity of Plasmodium falciparum isolates in Thailand to quinine and chloroquine, 1984-1990. Southeast Asian J. Trop. Med. Public Health. 23:1992;533-536. b.
391. Wood P.A., Eaton J.W. Hemoglobin catabolism and host-parasite heme balance in chloroquine-sensitive and chloroquine-resistant Plasmodium berghei infections. Am. J. Trop. Med. Hyg. 48:1993;465-472.
392. World Health Organisation (1990) Practical chemotherapy of malaria. Techical Report Series 805, p. 27, World Health Ogranisation, Geneva.
393. World Health Organisation Drug alert. halofantrine Weekly Epidemiol. Rec. 37:1993;1-2.
394. World Health Organisation (1997) The World Health Report. Conquering, Suffering, Enriching Humanity. World Health Organisation Publishers, Geneva.
395. Wozencraft A.O. Damage to malaria-infected erythrocytes following exposure to oxidant-generating systems. Parasitology. 92:1986;559-567.
396. Xu D.Y., Shen N.C., Li Y.T., Yin X.S., Chen Q., Yin M.Q., Li J., He S.F., Chou M.X., Gone J.Z. Studies on the new antimalarial drug, hydroxypiperaquine, and its phosphate. Shen J. Antimalarial Drugs in China. 1989;135-148 National Institutes of Pharmaceutical Research and Development, China.
397. Yayon A., Cabantchik Z.I., Ginsburg H. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3:1984;2695-2700. a.
398. Yayon A., Timberg R., Friedman S., Ginsburg H. Effects of chloroquine on the feeding mechanism of the intraerythrocytic human malarial parasite Plasmodium falciparum. J. Protozool. 31:1984;367-372. b.
399. Yayon A., Cabantchik Z.I., Ginsburg H. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc. Natl. Acad. Sci. USA. 82:1985;2784-2788.
400. Yuthavong Y., Panijpan B., Ruenwongsa P., Sirawaraporn W. Biochemical aspects of drug action and resistance in malaria parasites. Southeast Asian J. Trop. Med. Public Health. 16:1985;459-472.
401. Zalis M.G., Wilson C.M., Zhang Y., Wirth D.F. Characterization of the pfmdr2 gene for Plasmodium falciparum. Mol. Biochem. Parasitol. 62:1994;83-92.
402. Zarchin S., Krugliak M., Ginsburg H. Digestion of the host erythrocyte by malaria parasites is the primary target for quinoline-containing antimalarials. Biochem. Pharmacol. 35:1986;2435-2442.
403. Zhang K., Zhou J., Wu Z., Huang Q. Susceptibility of Plasmodium falciparum to chloroquine, piperaquine, amodiaquine, mefloquine and quinine with in vitro microtechnique in Hainan Island. Chin. J. Parasitol. Parasit. Dis. 5:1987;165-169.
404. Zhang Y., Hempelmann E. Lysis of malarial parasites and erythrocytes by ferriprotoporphyrin IX chloroquine and the inhibition of this effect by proteins. Biochem. Pharmacol. 36:1987;1267-1273.
405. Zhang Y., Asante K.S., Jung A. Stage-dependent inhibition of chloroquine on Plasmodium falciparum in vitro. J. Parasitol. 72:1986;830-836.
406. Zidovetski R., Sherman I.W., Atiya A., De Boeck H. A NMR study of interactions of 4-aminoquinoline on bilayers. Mol. Biochem. Parasitol. 35:1989;199-208.